Pathologic response and residual tumor cellularity after neo-adjuvant chemotherapy predict prognosis in breast cancer patients.

[1]  L. Buisseret,et al.  Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer , 2022, Cancers.

[2]  R. Gelber,et al.  Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis , 2021, BMJ.

[3]  Jianjun He,et al.  Nomogram-derived prediction of pathologic complete response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy (NCT) , 2020, BMC Cancer.

[4]  U. Dafni,et al.  Breast Cancer Statistics in the European Union: Incidence and Survival across European Countries , 2019, Breast Care.

[5]  S. Nayler,et al.  Pathological complete response in early breast cancer patients undergoing neoadjuvant chemotherapy: Focus on Ki-67 and molecular subtypes. , 2019, Annals of Oncology.

[6]  P. Fasching,et al.  Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer , 2019, The New England journal of medicine.

[7]  S. Sandoughdaran,et al.  Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients , 2018, Asian Pacific journal of cancer prevention : APJCP.

[8]  Vivek Verma,et al.  Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy , 2018, Breast Cancer Research and Treatment.

[9]  Sung-Bae Kim,et al.  Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy , 2017, The New England journal of medicine.

[10]  Kristine R Broglio,et al.  Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis. , 2016, JAMA oncology.

[11]  P. Jayalakshmy,et al.  Assessment of Pathological Response of Breast Carcinoma in Modified Radical Mastectomy Specimens after Neoadjuvant Chemotherapy , 2015, International journal of breast cancer.

[12]  Y. Matsuno,et al.  Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer , 2015, Breast Cancer.

[13]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[14]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Petra Macaskill,et al.  Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. , 2012, European journal of cancer.

[16]  P. Fasching,et al.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Edward Chu,et al.  A history of cancer chemotherapy. , 2008, Cancer research.

[18]  L. Pusztai,et al.  Residual specimen cellularity after neoadjuvant chemotherapy for breast cancer , 2007, The British journal of surgery.

[19]  Christos Hatzis,et al.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Norman Wolmark,et al.  Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  G. Hortobagyi,et al.  Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. , 2005, International journal of radiation oncology, biology, physics.

[22]  Roman Rouzier,et al.  Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response , 2004, Cancer.

[23]  A. Hutcheon,et al.  A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. , 2003, Breast.

[24]  J. Pierga,et al.  Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. the role of clinical response. , 2003, European journal of cancer.

[25]  G. Hortobagyi,et al.  Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience. , 2002, Clinical breast cancer.

[26]  Fiona J Gilbert,et al.  Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Bryant,et al.  Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. , 2001, Journal of the National Cancer Institute. Monographs.

[28]  G. Hortobagyi,et al.  Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. , 1998, The cancer journal from Scientific American.

[29]  G. Giaccone,et al.  Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. , 1998, British Journal of Cancer.

[30]  D. Wickerham,et al.  Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Z. Baloch,et al.  Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. , 1995, Journal of the American College of Surgeons.

[32]  P. Hurteloup,et al.  Inflammatory Breast Cancer: Pilot Study of Intensive Induction Chemotherapy (FEC‐HD) Results in a High Histologic Response Rate , 1993 .

[33]  A. Luini,et al.  Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. , 1990, Journal of the National Cancer Institute.

[34]  F. Puglisi,et al.  Post-neoadjuvant strategies in breast cancer: From risk assessment to treatment escalation. , 2019, Cancer treatment reviews.